Categories AlphaGraphs, Earnings, Health Care
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Friday reported a sharp fall in fourth-quarter revenues and adjusted earnings.
Total revenues plunged 31% year-over-year to $3.41 billion in the three months ended December 2022. Excluding REGEN-COV and Ronapreve, however, revenues increased by 14%.
The biotechnology firm’s fourth-quarter adjusted earnings nearly halved to $12.56 per share from $23.42 per share in the same period of 2021. Unadjusted profit was $1.20 billion or $10.50 per share, compared to $2.23 billion or $19.69 per share last year.
“In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets,” said the company’s CEO Leonard Schleifer.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
AAPL Earnings: Apple’s Q2 sales and profit beat estimates; iPhone sales down 10%
Apple Inc. (NASDAQ: AAPL) on Thursday reported better-than-expected profit and revenue for the second quarter of 2024. There was a 10% decrease in iPhone sales. The gadget giant reported revenues
Shopify (SHOP) is all set to report Q1 2024 results. Here’s what to expect
Over the years, Shopify Inc. (NYSE: SHOP) has steadily expanded its footprint in the online retail market through constant innovation, like the recent launch of a mobile POS device for
eBay (EBAY): A look at how the ecommerce company fared in Q1 2024
Shares of eBay Inc. (NASDAQ: EBAY) were down over 2% on Thursday. The company reported its earnings results for the first quarter of 2024 a day ago, with revenue and
